“Taste perception can vary significantly from person to person, limiting the generalizability of our results,” she said.

Gilead Sciences has reported promising two-year interim data from the ongoing Phase III ASSURE study of seladelpar in ...

New research argues that the oral alternative to injected semaglutide could also help improve the symptoms of diabetes and ...

Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...

Narcolepsy type 1 is a rare, chronic central nervous system disorder defined by a loss of orexin neurons, with common ...

A new research paper titled "Serine racemase expression profile in the prefrontal cortex and hippocampal subregions during ...

There are two sides to every coin. This holds particularly true for penny stocks, or tickers that trade for less than $5 per ...

Gilead Sciences shared more data on its $4.3 billion, near-approval liver disease prospect Wednesday, linking the candidate ...

Three recent studies dig into the complexities of drugs like Ozempic, Wegovy and Mounjaro and find use of GLP-1RAs is "not a ...

Eli Lilly (LLY) posts detailed mid-stage results highlighting the benefits of its weight loss drug tirzepatide against a ...

Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced the Company will participate in ...